Next Article in Journal
The Emerging Role of Nutritional Vitamin D in Secondary Hyperparathyroidism in CKD
Previous Article in Journal
Nesfatin-130-59 Injected Intracerebroventricularly Increases Anxiety, Depression-Like Behavior, and Anhedonia in Normal Weight Rats
Article Menu
Issue 12 (December) cover image

Export Article

Open AccessArticle
Nutrients 2018, 10(12), 1888; https://doi.org/10.3390/nu10121888

Administration of Momordica charantia Enhances the Neuroprotection and Reduces the Side Effects of LiCl in the Treatment of Alzheimer’s Disease

1
Department of Nursing, Mackay Junior College of Medicine, Nursing and Management, Taipei 11260, Taiwan
2
Department of Life Science, National Taiwan Normal University, Taipei 11677, Taiwan
3
Hualien District Agriculture Research and Extension Station, Hualien 97365, Taiwan
*
Author to whom correspondence should be addressed.
Received: 26 October 2018 / Revised: 14 November 2018 / Accepted: 28 November 2018 / Published: 3 December 2018
Full-Text   |   PDF [7250 KB, uploaded 6 December 2018]   |  
  |   Review Reports

Abstract

Recently, the use of natural food supplements to reduce the side effects of chemical compounds used for the treatment of various diseases has become popular. Lithium chloride (LiCl) has some protective effects in neurological diseases, including Alzheimer’s disease (AD). However, its toxic effects on various systems and some relevant interactions with other drugs limit its broader use in clinical practice. In this study, we investigated the in vitro and in vivo pharmacological functions of LiCl combined with Momordica charantia (MC) in the treatment of AD. The in vitro results show that the order of the neuroprotective effect is MC5, MC3, MC2, and MC5523 under hyperglycemia or tau hyperphosphorylation. Therefore, MC5523 (80 mg/kg; oral gavage) and/or LiCl (141.3 mg/kg; intraperitoneal injection) were applied to ovariectomized (OVX) 3×Tg-AD female and C57BL/6J (B6) male mice that received intracerebroventricular injections of streptozotocin (icv-STZ, 3 mg/kg) for 28 days. We found that the combined treatment not only increased the survival rate by reducing hepatotoxicity but also increased neuroprotection associated with anti-gliosis in the icv-STZ OVX 3×Tg-AD mice. Furthermore, the cotreatment with MC5523 and LiCl prevented memory deficits associated with reduced neuronal loss, gliosis, oligomeric Aβ level, and tau hyperphosphorylation and increased the expression levels of synaptic-related protein and pS9-GSK3β (inactive form) in the icv-STZ B6 mice. Therefore, MC5523 combined with LiCl could be a potential strategy for the treatment of AD. View Full-Text
Keywords: lithium chloride; Momordica charantia; streptozotocin; neuroprotection; survival; Alzheimer’s disease lithium chloride; Momordica charantia; streptozotocin; neuroprotection; survival; Alzheimer’s disease
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Huang, H.-J.; Chen, S.-L.; Chang, Y.-T.; Chyuan, J.-H.; Hsieh-Li, H.M. Administration of Momordica charantia Enhances the Neuroprotection and Reduces the Side Effects of LiCl in the Treatment of Alzheimer’s Disease. Nutrients 2018, 10, 1888.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Nutrients EISSN 2072-6643 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top